Table 3

Multivariate-adjusted Cox proportional hazard models for the outcomes

	HR	95% CI	p Value
End-stage renal disease
Diabetes mellitus	21.328	13.456 to 33.804	<0.001
Antiviral treatment	0.150	0.073 to 0.307	<0.001
Metropolitan hospital*	1.490	0.895 to 2.481	0.124
Community hospital*	1.925	1.143 to 3.243	0.014
Physician clinic*	0.684	0.315 to 1.486	0.338
Male gender	1.921	1.246 to 2.963	0.003
Hypertension	1.530	1.048 to 2.233	0.028
Hyperlipidaemia	0.424	0.157 to 1.148	0.091
Acute coronary syndrome
Hypertension	1.921	1.519 to 2.431	<0.001
Male gender	2.286	1.804 to 2.898	<0.001
Age, per year	1.033	1.023 to 1.044	<0.001
Diabetes mellitus	1.726	1.351 to 2.206	<0.001
COPD	1.289	1.043 to 1.593	0.019
Antiviral treatment	0.773	0.617 to 0.968	0.026
Thyroid disorder	1.324	0.955 to 1.837	0.091
Ischaemic stroke
Age, per year	1.064	1.049 to 1.080	<0.001
Diabetes mellitus	2.363	1.793 to 3.115	<0.001
Male gender	2.063	1.549 to 2.746	<0.001
Hypertension	2.006	1.513 to 2.660	<0.001
Antiviral treatment	0.617	0.458 to 0.831	0.001
Metropolitan hospital*	0.959	0.703 to 1.307	0.790
Community hospital*	0.937	0.662 to 1.325	0.712
Physician clinic*	0.500	0.312 to 0.800	0.004
Thyroid disorder	0.614	0.363 to 1.041	0.070
Catastrophic autoimmune diseases
Male gender	0.270	0.169 to 0.430	<0.001
NSAID	2.512	1.355 to 4.657	0.004
Thyroid disorder	2.026	1.266 to 3.243	0.003
Cirrhosis	1.597	1.017 to 2.506	0.041

*Compared with tertiary medical centres as the reference.
COPD, chronic obstructive pulmonary disease; NSAID, non-steroidal anti-inflammatory drug.